title: Treatment of relapsed and refractory Hodgkin Lymphoma.
abstract: Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%-20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies.
authors: German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany.
authors: Bastian
authors: B
authors: von Tresckow
authors: Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Medical College of Cornell University, New York, NY. Electronic address: moskowic@MSKCC.ORG.
authors: Craig H
authors: CH
authors: Moskowitz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D012008:Recurrence; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents
keywords: Autologous stem cell transplant; Brentuximab vedotin; High-dose chemotherapy; Hodgkin lymphoma; Relapse